Oncology Today with Dr Neil Love

Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00)

CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:
Introduction (0:00)
New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)
Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
Managing brain metastases in triple-negative breast cancer (6:30)
EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications